Other substances

Dupilumab

An anti-IL-4 human monoclonal antibody.

Phase of research

Potential treatment - theoretical effect

How it helps

Other treatment

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Dupilumab on DrugBank

Marketed as

DUPIXENT

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Drug repurposing for COVID-19 using machine learning and mechanistic models of signal transduction circuits related to SARS-CoV-2 infection Protein factor Small molecule Antibody In silico	in silico (machine learning)	13.49	Considered by the authors to be among the most relevant drugs identified in a machine-learning algorithm-based screening of compounds which considers causal protein-protein interactions, known drug targets, and specific signalling circuits in <a href=	Dec/11/2020

AI-suggested references

Link	Publication date
Transitioning From Immunosuppressants to Dupilumab in Pediatric Atopic Dermatitis.	May/12/2020
Evaluation of adult patients with atopic dermatitis treated with dupilumab: a single-center real-life experience.	May/14/2020
Moderate to severe atopic dermatitis in adolescents treated with dupilumab: a multicenter Italian real-world experience.	Jun/11/2021
Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy.	May/18/2021
Real-life effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.	Mar/24/2022
No evidence of increased risk for COVID-19 infection in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy	Jun/15/2020
COVID-19 in Patients with Atopic Dermatitis Treated with Dupilumab: Three Cases and a Literature Review	Sep/24/2021
Dupilumab, Severe Asthma Airway Responses, and SARS-CoV2 Serology	Nov/23/2020
COVID-19 symptoms are attenuated in moderate-to-severe atopic dermatitis patients treated with dupilumab	Aug/21/2020
Effects of lockdown on health of patients with severe atopic dermatitis treated with dupilumab	Oct/21/2020
SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab	Nov/05/2020
COVID-19 in a patient with severe asthma using mepolizumab.	Dec/21/2020
Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports	Jul/08/2020
Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment:a population-based cohort study	Dec/01/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04920916	Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients	Completed	Phase 2	May/25/2021	Jan/10/2022
Alternative id - HSR210184 Interventions - Biological: Dupilumab\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - UVA Health, Charlottesville, Virginia, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 40 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Recovery\|proportion of patients with eosinophilia\|Cumulative incidence of grade 3 and 4 clinical adverse events, serious adverse events (SAEs) or death\|percentage of SARS-CoV-2 PCR positivity\|change in Plasma total Immunoglobulin E (IgE) levels\|Change from baseline in C-reactive protein (CRP)\|Change from baseline in Ferritin\|Duration of hospitalization\|Change in Plasma cytokine levels\|Change in PaO2/SaO2 to FiO2 ratio\|All-cause mortality rate

Export (.csv)